European University Cyprus and Medochemie Sign Memorandum of Understanding
Strengthening research, education and innovation in health and pharmaceutical sciences
European University Cyprus (EUC) and Cyprus-based pharmaceutical company Medochemie Ltd have signed a Memorandum of Understanding (MoU) to develop joint activities in research, education, training and innovation.
The MoU was signed on behalf of European University Cyprus by Dr Christoforos Hadjikyprianou, CEO and President of the Council. Medochemie Ltd was represented by Dr Christakis Sergides, Director of Innovation and Corporate Social Responsibility (I and CSR), and Ms Yiota Andreou, Learning, Development and Wellbeing Assistant Manager.
The agreement strengthens links between the academic and research community and the Cypriot pharmaceutical industry, creating opportunities for applied research and the exchange of scientific knowledge and expertise.
Under the MoU, EUC and Medochemie will collaborate on research, education and professional development activities, with particular emphasis on health-related fields connected to pharmaceutical sciences. The agreement also provides for joint participation in research programmes funded by the Research and Innovation Foundation (RIF), the European Commission and other funding bodies.
The collaboration is expected to support Medochemie’s research, development and innovation activities while providing EUC researchers with opportunities to pursue applied research that addresses the needs of industry and society.
The signing of the MoU highlights the role of university-industry collaboration in generating new knowledge and translating it into practice. The shared aim is to develop innovative applications that contribute to Cyprus’s scientific and economic development and improve health and quality of life.